Bezard E - Search Results

1

Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations.

Dehay B, Bourdenx M, Gorry P, Przedborski S, Vila M, Hunot S, Singleton A, Olanow CW, Merchant KM, Bezard E, Petsko GA, Meissner WG. Dehay B, et al. Among authors: bezard e. Lancet Neurol. 2015 Aug;14(8):855-866. doi: 10.1016/S1474-4422(15)00006-X. Epub 2015 Jun 3. Lancet Neurol. 2015. PMID: 26050140 Free PMC article. Review.

2

The deafferented nonhuman primate is not a reliable model of intractable pain.

Pioli EY, Gross CE, Meissner W, Bioulac BH, Bezard E. Pioli EY, et al. Among authors: bezard e. Neurol Res. 2003 Mar;25(2):127-9. doi: 10.1179/016164103101201274. Neurol Res. 2003. PMID: 12635510

3

Compensatory regulation of striatal neuropeptide gene expression occurs before changes in metabolic activity of basal ganglia nuclei.

Meissner W, Dovero S, Bioulac B, Gross CE, Bezard E. Meissner W, et al. Among authors: bezard e. Neurobiol Dis. 2003 Jun;13(1):46-54. doi: 10.1016/s0969-9961(03)00011-1. Neurobiol Dis. 2003. PMID: 12758066

4

Neuroprotection for Parkinson's disease: a call for clinically driven experimental design.

Bezard E. Bezard E. Lancet Neurol. 2003 Jul;2(7):393. doi: 10.1016/s1474-4422(03)00432-0. Lancet Neurol. 2003. PMID: 12849115 No abstract available.

5

Enriched environment confers resistance to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and cocaine: involvement of dopamine transporter and trophic factors.

Bezard E, Dovero S, Belin D, Duconger S, Jackson-Lewis V, Przedborski S, Piazza PV, Gross CE, Jaber M. Bezard E, et al. J Neurosci. 2003 Dec 3;23(35):10999-1007. doi: 10.1523/JNEUROSCI.23-35-10999.2003. J Neurosci. 2003. PMID: 14657156 Free PMC article.

6

Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease.

Meissner W, Prunier C, Guilloteau D, Chalon S, Gross CE, Bezard E. Meissner W, et al. Among authors: bezard e. Mol Neurobiol. 2003 Dec;28(3):209-18. doi: 10.1385/MN:28:3:209. Mol Neurobiol. 2003. PMID: 14709785 Review.

7

High-frequency stimulation of both zona incerta and subthalamic nucleus induces a similar normalization of basal ganglia metabolic activity in experimental parkinsonism.

Benazzouz A, Tai CH, Meissner W, Bioulac B, Bezard E, Gross C. Benazzouz A, et al. Among authors: bezard e. FASEB J. 2004 Mar;18(3):528-30. doi: 10.1096/fj.03-0576fje. Epub 2004 Jan 8. FASEB J. 2004. PMID: 14715698

8

Neuroprotective strategies for Parkinson's disease: conceptual limits of animal models and clinical trials.

Meissner W, Hill MP, Tison F, Gross CE, Bezard E. Meissner W, et al. Among authors: bezard e. Trends Pharmacol Sci. 2004 May;25(5):249-53. doi: 10.1016/j.tips.2004.03.003. Trends Pharmacol Sci. 2004. PMID: 15120490 Review.

9

Temporal and spatial alterations in GPi neuronal encoding might contribute to slow down movement in Parkinsonian monkeys.

Leblois A, Meissner W, Bezard E, Bioulac B, Gross CE, Boraud T. Leblois A, et al. Among authors: bezard e. Eur J Neurosci. 2006 Aug;24(4):1201-8. doi: 10.1111/j.1460-9568.2006.04984.x. Eur J Neurosci. 2006. PMID: 16930445

10

Impact of chronic subthalamic high-frequency stimulation on metabolic basal ganglia activity: a 2-deoxyglucose uptake and cytochrome oxidase mRNA study in a macaque model of Parkinson's disease.

Meissner W, Guigoni C, Cirilli L, Garret M, Bioulac BH, Gross CE, Bezard E, Benazzouz A. Meissner W, et al. Among authors: bezard e. Eur J Neurosci. 2007 Mar;25(5):1492-500. doi: 10.1111/j.1460-9568.2007.05406.x. Eur J Neurosci. 2007. PMID: 17425575

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

355 results

Search Page

Filters